Moderna, Inc. — MRNA

Close PriceMarket CapP/E RatioForward P/E RatioImplied Growth*Implied Forward Growth*DividendP/B Ratio
$51.59$20.47B--12.3N/A--2.8

Latest Headlines

Revenue & Net Income

Revenue & Net Income
Date Revenue Net_Income EPS Last_Updated Revenue_Change Net_Income_Change EPS_Change
0 2020-12-31 $274M $-747M $-1.96 2024-02-03 03:17:10 N/A N/A N/A
1 2021-12-31 $18,875M $8,362M $30.31 2026-06-05 09:12:00 6788.7% -1219.4% -1646.4%
2 2022-12-31 $18,875M $8,362M $21.26 2026-06-05 09:12:00 0.0% 0.0% -29.9%
3 2023-12-31 $6,754M $-4,714M $-12.33 2026-06-05 09:12:00 -64.2% -156.4% -158.0%
4 2024-12-31 $3,199M $-3,561M $-9.28 2026-06-05 09:12:00 -52.6% -24.5% -24.7%
5 2025-12-31 $1,922M $-2,822M $-9.28 2026-06-05 09:12:00 -39.9% -20.8% 0.0%
6 TTM 2026-03-31 $2,204M $-3,194M $-8.14 2026-05-05 08:51:33 14.7% 13.2% -12.3%

EPS

EPS

Forecasts

Revenue/Net Income Forecast EPS Forecast

Y/Y % Change

Revenue YoY Change EPS YoY Change
YoY Growth Rates

MRNA Year-over-Year Growth

  2020 2021 2022 2023 2024 2025 2026 2027 Average
Revenue Growth (%) 6788.7% 0.0% -64.2% -52.6% -39.9% 8.6% 20.4% 951.6%
Revenue Analysts (#) 0 0 0 0 0 0 22 21
EPS Growth (%) -1219.4% 0.0% -156.4% -24.5% -20.8% 21.6% -45.4% -206.4%
EPS Analysts (#) 0 0 0 0 0 0 21 20

Forward Estimate History

How the next-FY EPS and revenue estimates have drifted over time. One line per fiscal year – past lines end when that FY became current.

Forward EPS projection history by FY Forward revenue projection history by FY

Expenses

Revenue vs Expenses
Year Revenue ($) Cost of Revenue ($) R&D ($) SG&A ($) Facilities / D&A ($)
2022 $18.9B $5.1B $3.3B $1.1B $348.0M
2023 $6.8B $4.1B $4.8B $1.5B $621.0M
2024 $3.2B $1.3B $4.5B $1.2B $189.0M
2025 $1.9B $653.0M $3.1B $1.0B $215.0M
TTM $2.2B $1.5B $2.9B $979.0M $235.0M
Expenses % of Revenue
Year Revenue Change (%) Cost of Revenue Change (%) R&D Change (%) SG&A Change (%) Facilities / D&A Change (%)
2023 -64.22 -19.65 47.04 36.84 78.45
2024 -52.64 -68.69 -6.23 -24.21 -69.57
2025 -39.92 -48.78 -31.06 -13.29 13.76
TTM 14.67 129.40 -6.61 -3.83 9.30
No unmapped expenses.

Segment Performance

axis1_MRNA_Product_Sales.png axis1_MRNA_C_O_V_I_D19.png axis1_MRNA_Product_And_Service_Other.png axis1_MRNA_Grant.png axis1_MRNA_Collaboration_Arrangement_Including_Arrangements_With_Affiliate.png axis1_MRNA_R_S_V.png axis1_MRNA_License_And_Royalty.png axis1_MRNA_Stand_Ready_Manufacturing_Revenue.png
SEGMENTS v2025-09-09 · 2026-06-05 09:12 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).
Year Product Sales Rev C O V I D19 Rev Product And Service Other Rev Grant Rev Collaboration Arrangement Including Arrangements With Affiliate Rev R S V Rev License And Royalty Rev Stand Ready Manufacturing Revenue Rev Total Rev
2023 33.4B 6.67B 0.35B 0.28B 0.25B – – – 40.9B
2024 15.5B 3.08B 0.28B 0.11B 0.14B 0.03B 0.04B – 19.2B
2025 9.09B 1.81B 0.25B 0.07B 0.04B 0.01B 0.01B 0.08B 11.4B
TTM 26.8B 5.32B 0.62B 0.46B 0.19B 0.04B – – 33.5B
% of Total (TTM) 80.2% 15.9% 1.9% 1.4% 0.6% 0.1% – – 100%

Balance Sheet

Balance Sheet
  Metric Value
0 Total Assets $11,488M
1 Cash $1,908M
2 Total Liabilities $4,080M
3 Total Debt $1,298M
4 Total Equity $7,408M
5 Debt to Equity Ratio 0.18

EPS & Dividend

EPS & Dividend

Valuation

Valuation
Share Price Treasury Yield Estimates Fair Value (P/E) Fair Value (P/S) Current P/S Current P/E
$51.59 4.5% Nicks Growth: 8%
Nick's Expected Margin: 10%
FINVIZ Growth: 26%		 Nicks: 14
Finviz: 72		 Nick's: 1.414 9.3 -
Basis Year Nicks Valuation Nicks vs Share Price Finviz Valuation Finviz vs Share Price
$5.55 Revenue TTM $7.85 -84.8% $39.83 -22.8%
$5.26 Revenue 2026 $7.44 -85.6% $37.71 -26.9%
$6.33 Revenue 2027 $8.95 -82.7% $45.39 -12.0%

Implied Growth

Implied Growth
No implied growth data available.

← Back